The addition of Rituximab (R) to combination chemotherapy (CT) significantly improves the treatment of mantle cell lymphomas (MCL):: Results of two prospective randomized studies by the German Low Grade Lymphoma Study Group (GLSG).

被引：0

作者：

Hiddemann, W ^{[1
]}

Unterhalt, M ^{[1
]}

Dreyling, M ^{[1
]}

Hossfeld, DK ^{[1
]}

Lengfelder, E ^{[1
]}

Metzner, B ^{[1
]}

Pfreundschuh, M ^{[1
]}

Kneba, M ^{[1
]}

Fricke, HJ ^{[1
]}

Böck, HP ^{[1
]}

Schmitz, N ^{[1
]}

Koch, P ^{[1
]}

Fuchs, R ^{[1
]}

机构：

[1] Univ Munich, Klinikum Grosshadern, Dept Internal Med 3, GLSG, D-8000 Munich, Germany

来源：

BLOOD | 2002年 / 100卷 / 11期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

339

引用

页码：92A / 92A

页数：1

共 50 条

[21] The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG)
C Buske
E Hoster
M Dreyling
H Eimermacher
H Wandt
B Metzner
R Fuchs
J Bittenbring
B Woermann
K Hohloch
G Hess
W-D Ludwig
J Schimke
S Schmitz
M Kneba
M Reiser
U Graeven
W Klapper
M Unterhalt
W Hiddemann
Leukemia, 2009, 23 : 153 - 161
[22] Chemotherapy-Free Combination of Obinutuzumab and Ibrutinib in First LINE Treatment of Follicular Lymphoma. the Alternative Study By the German Low Grade Lymphoma Study Group (GLSG)
Schmidt, Christian
Zoellner, Anna-Katharina
Jurinovic, Vindi
Soekler, Martin
Forstpointner, Roswitha
Haubner, Sascha
Buske, Christian
Viardot, Andreas
Keller, Ulrich
Pott, Christiane
Graeven, Ullrich
Marks, Reinhard
Haenel, Mathias
Liersch, Ruediger
Duerig, Jan
Hoster, Eva
Unterhalt, Michael
Hiddemann, Wolfgang
BLOOD, 2018, 132
[23] The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG)
Buske, C.
Hoster, E.
Dreyling, M.
Eimermacher, H.
Wandt, H.
Metzner, B.
Fuchs, R.
Bittenbring, J.
Woermann, B.
Hohloch, K.
Hess, G.
Ludwig, W-D
Schimke, J.
Schmitz, S.
Kneba, M.
Reiser, M.
Graeven, U.
Klapper, W.
Unterhalt, M.
Hiddemann, W.
LEUKEMIA, 2009, 23 (01) : 153 - 161
[24] MCP (Mitoxantrone/Chlorambucil/Prednisolone) chemotherapy impairs the subsequent collection of stem cells in comparison to CHOP induction in patients with indolent lymphomas -: Results of a prospective randomized trial of the German low grade lymphoma study group (GLSG).
Nickenig, C
Dreyling, M
Hoster, E
Pfreundschuh, M
Truemper, L
Reiser, M
Wandt, H
Unterhalt, M
Hiddemann, W
BLOOD, 2005, 106 (11) : 931A - 931A
[25] Prognostic determinants for long term outcome of low grade follicular lymphomas after cytoreductive chemotherapy and interferon alpha maintenance. Results of the German Low Grade Lymphoma Study Group (GLSG).
Unterhalt, M
Hermann, R
Koch, P
Trumper, L
Bodenstein, H
Dietzfelbinger, H
Landys, K
Reuss, M
Vetter, H
Maschmeyer, G
Freund, M
Neubauer, A
Engert, A
Stauder, R
Herold, M
Tiemann, M
Parwaresch, R
Stein, H
Hiddemann, W
BLOOD, 1997, 90 (10) : 1743 - 1743
[26] Combined immuno-chemotherapy (R-CHOP) results in significantly superior response rates and time to treatment failure in first line treatment of patients with lymphomplasmocytoid/ic immumocytoma (LP-IC) -: Results of a prospective randomized trial of the German Low grade Lymphoma Study Group (GLSG).
Buske, C
Dreyling, MH
Eimermacher, H
Boeck, HP
Pfreundschuh, M
Metzner, B
Fuchs, R
Woermann, B
Truemper, LH
Hess, G
Wandt, H
Ludwig, WD
Kreuser, ED
Schimke, J
Weh, HJ
Schmitz, S
Schmiegel, W
Unterhalt, M
Hiddemann, W
BLOOD, 2004, 104 (11) : 50A - 50A
[27] Allogeneic stem cell transplantation with dose-reduced conditioning in relapsed follicular and mantle cell lymphoma - A prospective phase II trial of the German low grade lymphoma study group (GLSG)
Dreyling, Martin H.
Beelen, D. -W.
Schleuning, Michael
Ho, Anthony D.
Gramatzki, Martin
Glas, B.
Pfreundschuh, Michael
Wilhelm, Martin
Schmitz, Norbert
Kolb, Hans-Jochem
Unterhalt, Michael
Hiddemann, Wolfgang
BLOOD, 2007, 110 (11) : 899A - 899A
[28] Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas:: Results of a prospective comparative analysis of the German low-grade lymphoma study group
Hiddemann, W
Unterhalt, M
Hermann, R
Wöltjen, HH
Kreuser, ED
Trümper, L
Reuss-Borst, M
Terhardt-Kasten, E
Busch, M
Neubauer, A
Kaiser, U
Hanrath, RD
Middeke, H
Helm, G
Freund, M
Stein, H
Tiemann, M
Parwaresch, R
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (05) : 1922 - 1930
[29] Myeloablative radiochemotherapy followed by blood-stemcell-transplantation significantly prolongs the disease-free interval in patients with low-grade lymphomas as compared to standard maintenance with interferon alpha:: Results of a prospective randomized comparison by the German low grade lymphoma study group (GLSG).
Hiddemann, W
Unterhalt, M
Wandt, H
Huber, C
Dörken, B
Kuse, R
Pfeundschuh, M
Parwaresch, R
BLOOD, 1999, 94 (10) : 610A - 611A
[30] Bendamustine/mitoxantrone/rituximab (BMR): A very effective and well tolerated immuno-chemotherapy for relapsed and refractory indolent lymphomas - Results of a Multicentre phase-II-study of the German low grade lymphoma study group (GLSG).
Weide, R
Koeppler, H
Heymanns, J
Thomalla, J
Hess, G
Gamm, H
Aldaoud, A
Schmitz, S
Haak, U
Plewe, D
Burkhard, O
Gaede, B
Hinrichs, F
Pflueger, KH
Dreyling, M
Unterhalt, M
Hiddemann, W
BLOOD, 2004, 104 (11) : 681A - 681A

← 1 2 3 4 5 →